Spots Global Cancer Trial Database for egfr gene mutation

Every month we try and update this database with for egfr gene mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients	NCT04552613	Non-small-lung-... NSCLC EGFR Gene Mutat...	EGFR-TKI EGFR-TKI combin...	18 Years - 80 Years	The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Clinical Trial of YH25448 in Patients With EGFR Mutation Positive Advanced NSCLC	NCT03046992	EGFR Gene Mutat...	YH25448	20 Years -	Yuhan Corporation
D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC	NCT04206072	Non-Small Cell ... EGFR Gene Mutat...	D-0316 Capsule Icotinib Hydroc...	18 Years -	Betta Pharmaceuticals Co., Ltd.
A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations	NCT06362980	NSCLC	BPI-1178 Osimertinib	18 Years -	National Cancer Center, China
Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma	NCT01565538	Lung Cancer	Erlotinib Pemetrexed	18 Years - 75 Years	Sun Yat-sen University
The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib	NCT04640870	Non Small Cell ... EGF-R Positive ... EGFR Gene Mutat...	Afatinib	18 Years -	Hellenic Cooperative Oncology Group
Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA	NCT02629523	Lung Neoplasms EGFR Gene Mutat...	Afatinib	19 Years -	Chonnam National University Hospital
Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients	NCT04552613	Non-small-lung-... NSCLC EGFR Gene Mutat...	EGFR-TKI EGFR-TKI combin...	18 Years - 80 Years	The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer	NCT03396185	EGFR Gene Mutat... Non Small Cell ... Non Small Cell ...	Icotinib	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA	NCT02629523	Lung Neoplasms EGFR Gene Mutat...	Afatinib	19 Years -	Chonnam National University Hospital
The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC	NCT06117644	Non Small Cell ... EGFR Gene Mutat... Non Small Cell ... Non-small Cell ...	Furmonertinib	18 Years -	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment	NCT04882345	Lung Cancer EGFR Gene Mutat...	Almonertinib	18 Years - 75 Years	Shanghai Chest Hospital
The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC	NCT06117644	Non Small Cell ... EGFR Gene Mutat... Non Small Cell ... Non-small Cell ...	Furmonertinib	18 Years -	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)	NCT02338011	Non-Small Cell ... Brain Metastase... EGFR Gene Mutat...	Gefitinib WBRT	18 Years -	Shanghai Chest Hospital
Clinical Trial of YH25448 in Patients With EGFR Mutation Positive Advanced NSCLC	NCT03046992	EGFR Gene Mutat...	YH25448	20 Years -	Yuhan Corporation
Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.	NCT06238882	Non-small Cell ... Brain Metastase... EGFR Gene Mutat...	Nitroglycerin	18 Years - 85 Years	Instituto Nacional de Cancerologia de Mexico
Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer	NCT04013542	ALK Gene Rearra... EGFR Gene Mutat... Locally Advance... Lung Non-Small ... Stage II Lung C... Stage IIA Lung ... Stage IIB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Unresectable Lu...	Ipilimumab Nivolumab Radiation Thera...	18 Years -	M.D. Anderson Cancer Center
Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC	NCT06436144	Non Small Cell ... EGFR Gene Mutat... Non Small Cell ... Non-small Cell ...	Osimertinib	18 Years - 80 Years	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Doxycycline vs Isotretinoin for Acneiform Eruptions of TKI	NCT04864717	Acneiform Erupt... Cancer, Treatme...	Doxycycline 100... Isotretinoin 40...	18 Years -	Lady Davis Institute
Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer	NCT04592666	Lung Cancer, No... EGFR T790M EGFR Gene Mutat...	Almonertinib Pemetrexed Carboplatin	18 Years - 75 Years	Fudan University
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases	NCT03653546	Non-small Cell ... EGFR Gene Mutat... Brain Metastase...	AZD3759 Erlotinib Gefitinib	18 Years -	Alpha Biopharma (Jiangsu) Co., Ltd.
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases	NCT03653546	Non-small Cell ... EGFR Gene Mutat... Brain Metastase...	AZD3759 Erlotinib Gefitinib	18 Years -	Alpha Biopharma (Jiangsu) Co., Ltd.
A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC	NCT05698264	Non Small Cell ... EGFR Gene Mutat... Immune Checkpoi...	concomitant TTF... concomitant TTF...	18 Years -	Shaare Zedek Medical Center
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies	NCT04042558	NSCLC Stage III... NSCLC Stage IV EGFR Gene Mutat... ALK Gene Rearra... ROS1 Gene Mutat...	Carboplatin + P... Carboplatin + P...	18 Years - 75 Years	Centre Francois Baclesse
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	NCT04862780	Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla...	BLU-945 osimertinib	18 Years -	Blueprint Medicines Corporation
Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations	NCT04695925	Non-small Cell ... EGFR Gene Mutat...	Osimertinib 80 ... Pemetrexed 500 ... Carboplatin	18 Years -	Sun Yat-sen University
Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC	NCT06436144	Non Small Cell ... EGFR Gene Mutat... Non Small Cell ... Non-small Cell ...	Osimertinib	18 Years - 80 Years	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients	NCT04512430	Non Small Cell ... EGFR Gene Mutat...	Atezolizumab Bevacizumab Carboplatin Pemetrexed	18 Years -	Fundación GECP
Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC	NCT05394233	Non-squamous No... EGFR Gene Mutat...	Tislelizumab Co...	18 Years - 75 Years	Sichuan Cancer Hospital and Research Institute
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.	NCT03755102	EGFR Gene Mutat... Lung Cancer Lung Cancer Met...	Dacomitinib Osimertinib	18 Years -	Memorial Sloan Kettering Cancer Center
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)	NCT05598528	Lung Cancer, No... EGFR Gene Mutat... EGFR-TKI Resist... Primary Resista... Circulating Tum...	Genomic profile... circulating tum...	18 Years -	Second Xiangya Hospital of Central South University
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma	NCT05503667	Lung Adenocarci... Lung Adenocarci... EGFR Gene Mutat...	Furmonertinib Bevacizumab	18 Years -	Shanghai Pulmonary Hospital, Shanghai, China
EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism	NCT03002844	Nonsmall Cell L... EGFR Gene Mutat...	EGFR-TK Inhibit... EGFR-TKI EGFR-TKI and Ch...	18 Years - 70 Years	Shanghai Pulmonary Hospital, Shanghai, China
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC	NCT05153408	Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR C797S EGFR C797A EGFR L858R EGFR Exon 19 De... EGFR Gene Mutat... EGF-R Positive ... EGFR Mutation R... EGFR Activating... Thoracic Neopla... Antineoplastic ... Protein Kinase ... EGFR C797G EGFR C797X Non Small Cell ...	BLU-701 osimertinib carboplatin pemetrexed	18 Years -	Blueprint Medicines Corporation
The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib	NCT04640870	Non Small Cell ... EGF-R Positive ... EGFR Gene Mutat...	Afatinib	18 Years -	Hellenic Cooperative Oncology Group
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer	NCT04085315	Lung Cancer Met... EGFR Gene Mutat...	Osimertinib Alisertib	18 Years -	University of California, San Francisco
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)	NCT05598528	Lung Cancer, No... EGFR Gene Mutat... EGFR-TKI Resist... Primary Resista... Circulating Tum...	Genomic profile... circulating tum...	18 Years -	Second Xiangya Hospital of Central South University
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells	NCT06186401	EGFR Gene Mutat... Glioblastoma MGMT-Unmethylat... Recurrent Gliob...	E-SYNC T Cells Cyclophosphamid... Fludarabine (no... Leukapheresis Surgical resect...	18 Years -	University of California, San Francisco
Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations	NCT04695925	Non-small Cell ... EGFR Gene Mutat...	Osimertinib 80 ... Pemetrexed 500 ... Carboplatin	18 Years -	Sun Yat-sen University
Applying Mobile Healthcare Education to Improve Cutaneous Self-care Capability	NCT06291688	EGFR Gene Mutat... Drug-Related Si... Cancer, Treatme... Cancer	Mobile healthca... Mobile healthca...	18 Years -	National Taiwan University Hospital
The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib	NCT04640870	Non Small Cell ... EGF-R Positive ... EGFR Gene Mutat...	Afatinib	18 Years -	Hellenic Cooperative Oncology Group
Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies	NCT05370469	Lung Cancer EGFR Gene Mutat... EGFR ALK Gene Mutati... RET Gene Mutati... MET Gene Mutati... KRAS Mutation-R... BRAF ROS1 Gene Mutat...	Sensus Smartwat... RX Cap Fitbit Sense Surveys	18 Years -	University of Virginia
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma	NCT05503667	Lung Adenocarci... Lung Adenocarci... EGFR Gene Mutat...	Furmonertinib Bevacizumab	18 Years -	Shanghai Pulmonary Hospital, Shanghai, China
Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients	NCT03171636	Lung Neoplasms KRAS Gene Mutat... EGFR Gene Mutat...		18 Years -	Hospital Erasto Gaertner
Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers	NCT02098954	Carcinoma, Non-... EGFR Gene Mutat...	Gemcitabine pla...	18 Years - 75 Years	Hunan Province Tumor Hospital
A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases	NCT05033691	NSCLC EGFR Gene Mutat... EGF-R Positive ... Non-small Cell ... Brain Metastase...	Stereotactic su...	18 Years - 120 Years	Hadassah Medical Organization
Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT	NCT06222489	Non-Small Cell ... Advanced Non-Sm... EGFR Gene Mutat...	89Zr-Patritumab...	18 Years -	The Netherlands Cancer Institute
Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.	NCT06018688	Non Small Cell ... EGFR Gene Mutat...	Osimertinib Aspirin	18 Years -	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)	NCT06323148	Lung Cancer EGFR Gene Mutat... Minimal Residua...	Osimertinib No adjuvant the...	18 Years -	Fudan University
A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations	NCT06362980	NSCLC	BPI-1178 Osimertinib	18 Years -	National Cancer Center, China
Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients	NCT03171636	Lung Neoplasms KRAS Gene Mutat... EGFR Gene Mutat...		18 Years -	Hospital Erasto Gaertner
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	NCT04862780	Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla...	BLU-945 osimertinib	18 Years -	Blueprint Medicines Corporation
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients	NCT06071013	Non-small Cell ... EGFR Gene Mutat... EGFR-TKI Resist...	Nintedanib, gef...	20 Years - 70 Years	China Medical University Hospital
EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism	NCT03002844	Nonsmall Cell L... EGFR Gene Mutat...	EGFR-TK Inhibit... EGFR-TKI EGFR-TKI and Ch...	18 Years - 70 Years	Shanghai Pulmonary Hospital, Shanghai, China
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells	NCT06186401	EGFR Gene Mutat... Glioblastoma MGMT-Unmethylat... Recurrent Gliob...	E-SYNC T Cells Cyclophosphamid... Fludarabine (no... Leukapheresis Surgical resect...	18 Years -	University of California, San Francisco
Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment	NCT06095934	NSCLC EGFR Gene Mutat...	neo-antigen vac...	18 Years -	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma	NCT03071705	Non-Small Cell ... Tyrosine Kinase... EGFR Gene Mutat...	Metformin TKI	18 Years - 99 Years	Instituto Nacional de Cancerologia de Mexico
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients	NCT06071013	Non-small Cell ... EGFR Gene Mutat... EGFR-TKI Resist...	Nintedanib, gef...	20 Years - 70 Years	China Medical University Hospital
Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma	NCT03071705	Non-Small Cell ... Tyrosine Kinase... EGFR Gene Mutat...	Metformin TKI	18 Years - 99 Years	Instituto Nacional de Cancerologia de Mexico
Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma	NCT01565538	Lung Cancer	Erlotinib Pemetrexed	18 Years - 75 Years	Sun Yat-sen University
Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT	NCT06222489	Non-Small Cell ... Advanced Non-Sm... EGFR Gene Mutat...	89Zr-Patritumab...	18 Years -	The Netherlands Cancer Institute
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies	NCT04042558	NSCLC Stage III... NSCLC Stage IV EGFR Gene Mutat... ALK Gene Rearra... ROS1 Gene Mutat...	Carboplatin + P... Carboplatin + P...	18 Years - 75 Years	Centre Francois Baclesse
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy	NCT03042221	Non-Small Cell ... Non-Small Cell ... EGFR Gene Mutat... ALK Gene Mutati... ROSE Cluster 1 BRAF V600E		18 Years - 85 Years	University of Colorado, Denver
The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC	NCT06117644	Non Small Cell ... EGFR Gene Mutat... Non Small Cell ... Non-small Cell ...	Furmonertinib	18 Years -	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC	NCT05394233	Non-squamous No... EGFR Gene Mutat...	Tislelizumab Co...	18 Years - 75 Years	Sichuan Cancer Hospital and Research Institute
Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer	NCT05517083	Non Small Cell ... EGFR Gene Mutat...	Ultarthin bronc...	20 Years -	Pusan National University Hospital
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma	NCT05503667	Lung Adenocarci... Lung Adenocarci... EGFR Gene Mutat...	Furmonertinib Bevacizumab	18 Years -	Shanghai Pulmonary Hospital, Shanghai, China
Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma	NCT01565538	Lung Cancer	Erlotinib Pemetrexed	18 Years - 75 Years	Sun Yat-sen University
Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma	NCT04201756	Lung Adenocarci... EGFR Gene Mutat...	Afatinib	18 Years -	Shanghai Pulmonary Hospital, Shanghai, China

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: